Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma

Epidermal growth factor receptor (EGFR)‐mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third‐generation EGFR‐tyrosine kinase inhibitor, osimertinib, is effective in EGFR‐mutated lung adenocarcinoma, but its efficacy in EGFR‐mutated lung SCC is unclear. The patient was...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Tadashi, Fujiwara, Takumi, Fujimoto, Hajime, Tarumi, Hirotoshi, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Naito, Masahiro, Okugawa, Yoshinaga, Yasuma, Taro, Gabazza, Esteban Cesar, Oomoto, Yasuhiro, Kobayashi, Tetsu, Ibata, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981312/
https://www.ncbi.nlm.nih.gov/pubmed/36710365
http://dx.doi.org/10.1111/1759-7714.14807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981312/
https://www.ncbi.nlm.nih.gov/pubmed/36710365
http://dx.doi.org/10.1111/1759-7714.14807

Ejemplares similares